江苏恩华药业股份有限公司 2017 年年度报告全文 江苏恩华药业股份有限公司 2017 年年度报告 2018 年 02 月 1 江苏恩华药业股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异，注意投资风险。 1、产品招标风险。2018 年尚未招标的省份将陆续开展药品招标工作，但是 各省份的招标方案和实际执行依然存在着很大的不确定性，这将对公司部分近 年上市的新产品的销售造成影响。 2、药品降价风险。由于各地招标过程中价格仍然是中标的关键因素，这将 造成投标企业间竞相压价，这会造成公司参与招标的产品存在降价 ...

江苏恩华药业股份有限公司 2017 年第三季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2017-032 江苏恩华药业股份有限公司 2017 年第三季度报告正文 1 江苏恩华药业股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,319,850,888.97 | | 2,974,889,940.25 | 11.60% | | 归 ...

江苏恩华药业股份有限公司 2017 年半年度报告全文 江苏恩华药业股份有限公司 2017 年半年度报告 2017 年 07 月 1 江苏恩华药业股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 请投资者注意阅读并关注以下重大风险： 1、产品招标风险。2017 年尚未招标的省份将陆续开展药品招标工作，但是 各省份的招标方案和实际执行依然存在着很大的不确定性，这将对公司部分近 年上市的新产品的销售造成影响。 2、药品降价风险。由于各地招标过程中价格仍然是中标的关键因素，这将 造成投标企业间竞相压价，这会造成公司参与招标的产品存在降价的风险，给 公司的未来增长带来不 ...

江苏恩华药业股份有限公司 2017 年第一季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2017-016 江苏恩华药业股份有限公司 2017 年第一季度报告正文 1 江苏恩华药业股份有限公司 2017 年第一季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 第一节 重要提示 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 838,300,742.74 | 758,919,365.69 | 10.46% | | 归属 ...

江苏恩华药业股份有限公司 2016 年年度报告全文 江苏恩华药业股份有限公司 2016 年年度报告 2017 年 02 月 1 江苏恩华药业股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异，注意投资风险。 请投资者注意阅读并关注以下重大风险： 1、产品招标风险。2017 年尚未招标的省份将陆续开展药品招标工作，但是 各省份的招标方案和实际执行依然存在着很大的不确定性，这将对公司部分近 年上市的新产品的销售造成影响。 2、药品降价风险。由于各地招标过程中价格仍然是中标的关键因素，这将 造成投标企业间竞相 ...

江苏恩华药业股份有限公司 2016 年第三季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2016-061 一、主要会计数据和财务指标 江苏恩华药业股份有限公司 2016 年第三季度报告正文 1 江苏恩华药业股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,882,403,939.67 | 2,550,922,408. ...

江苏恩华药业股份有限公司 2016 年半年度报告全文 江苏恩华药业股份有限公司 2016 年半年度报告 2016 年 07 月 1 江苏恩华药业股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 2 | 目录 | | --- | | 2016 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 20 | | 第五节 | 重要事项 26 | | 第六节 | ...

江苏恩华药业股份有限公司 2016 年第一季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2016-021 江苏恩华药业股份有限公司 2016 年第一季度报告正文 1 江苏恩华药业股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 758,919,365.69 | 674,832,087.12 | 12.46% | | 归属于上市公司股东的净利润（元） | 70,265,337.24 | 60,042,756. ...

江苏恩华药业股份有限公司 2015 年年度报告全文 江苏恩华药业股份有限公司 2015 年年度报告 2016 年 02 月 1 江苏恩华药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 1、产品招标风险。2016 年尚未招标的省份将陆续开展药品招标工作，各地 招标方案和实际执行依然存在着很大的不确定性，各地招标过程中价格仍然是 中标的关键因素，这将造成投标企业间竞相压价，公司在争取到更多市场份额 的同时，亦会造成部分品种毛利率的下降。 2、市场竞争格局发生变化的风险。国家基本药物目录调整将带来市场竞争 格局的变化，导致市场竞争变化的不确定性，也会给公司的增长带来 ...

[Important Notice](index=2&type=section&id=Item%201.%20Important%20Notice) The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content, assuming legal responsibility for any false statements, misleading representations, or major omissions - The company's head, Sun Pengsheng, chief accountant, Gao Aihao, and head of accounting, Hu Jirui, declare that the financial statements in the quarterly report are true, accurate, and complete[4](index=4&type=chunk) [Key Financial Data and Shareholder Changes](index=3&type=section&id=Item%202.%20Key%20Financial%20Data%20and%20Shareholder%20Changes) The company's total assets and net assets attributable to shareholders significantly increased, with steady growth in operating revenue and net profit, while net cash flow from operating activities decreased [Key Accounting Data and Financial Indicators](index=3&type=section&id=Item%202.1.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) At the end of the reporting period, the company's total assets and net assets attributable to shareholders of the listed company showed significant year-on-year growth, with operating revenue and net profit also achieving steady increases, while net cash flow from operating activities decreased, and basic and diluted earnings per share improved Key Accounting Data and Financial Indicators (Balance Sheet Section) | Indicator | End of Reporting Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 2,609,460,869.80 | 1,922,656,263.98 | 35.72% | | Net Assets Attributable to Shareholders of Listed Company | 1,772,165,599.39 | 1,043,287,238.27 | 69.86% | Key Accounting Data and Financial Indicators (Income Statement and Cash Flow Statement Section) | Indicator | Current Reporting Period (RMB) | Change from Prior Year Same Period | Year-to-Date (RMB) | Year-to-Date Change from Prior Year Same Period | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 680,857,844.76 | 10.81% | 2,025,174,180.09 | 10.51% | | Net Profit Attributable to Shareholders of Listed Company | 69,533,623.78 | 18.53% | 215,884,867.21 | 18.39% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 69,285,836.04 | 18.11% | 215,326,800.73 | 18.09% | | Net Cash Flow from Operating Activities | -- | -- | 97,255,513.06 | -17.08% | | Basic Earnings Per Share (RMB/share) | 0.1433 | 18.53% | 0.4450 | 18.41% | | Diluted Earnings Per Share (RMB/share) | 0.1433 | 18.53% | 0.4450 | 18.41% | | Weighted Average Return on Net Assets | 5.76% | -0.34% | 19.01% | -0.83% | Non-recurring Gains and Losses Items and Amounts | Item | Year-to-Date Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 11,490.27 | | | Government Subsidies Recognized in Current Profit and Loss | 300,000.00 | | | Other Non-operating Income and Expenses Apart from the Above | 464,969.24 | | | Less: Income Tax Impact | 153,728.51 | | | Impact on Minority Interests (After Tax) | 64,664.52 | | | Total | 558,066.48 | -- | [Total Number of Shareholders and Top Ten Shareholders' Holdings at the End of the Reporting Period](index=4&type=section&id=Item%202.2.%20Total%20Shareholders%20and%20Top%20Ten%20Holdings) As of the end of the reporting period, the company had 10,279 common shareholders, with Xuzhou Enhua Investment Co., Ltd. being the largest shareholder at 40.09% ownership, and the actual controllers collectively holding 60.95% of the company's shares through direct and indirect means, acting in concert Total Number of Common Shareholders at the End of the Reporting Period | Total Number of Common Shareholders at the End of the Reporting Period | | :--- | | 10,279 | Top 10 Common Shareholders' Holdings | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held | Number of Restricted Shares Held | Pledge or Freeze Status | Quantity | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Xuzhou Enhua Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 40.09% | 194,503,039 | 0 | | | | Sun Pengsheng | Domestic Natural Person | 4.77% | 23,127,085 | 17,345,313 | | | | Qi Chao | Domestic Natural Person | 4.45% | 21,613,848 | 16,210,385 | Pledge | 15,600,000 | | Chen Zengliang | Domestic Natural Person | 3.96% | 19,196,438 | 14,397,328 | | | | Fu Qing | Domestic Natural Person | 3.96% | 19,196,436 | 14,397,326 | | | | Yang Ziliang | Domestic Natural Person | 3.72% | 18,044,440 | 13,533,330 | | | | Li Wei | Domestic Natural Person | 2.59% | 12,550,000 | 0 | | | | China Merchants Bank Co., Ltd. - Huatiamfu Medical Service Flexible Allocation Mixed Securities Investment Fund | Other | 2.43% | 11,809,102 | 0 | | | | Goldman, Sachs & Co. | Overseas Legal Person | 1.96% | 9,494,934 | 0 | | | | Ma Wusheng | Domestic Natural Person | 1.42% | 6,876,944 | 0 | | | Top 10 Unrestricted Common Shareholders' Holdings | Shareholder Name | Number of Unrestricted Common Shares Held | Share Type | Quantity | | :--- | :--- | :--- | :--- | | Xuzhou Enhua Investment Co., Ltd. | 194,503,039 | RMB Common Shares | 194,503,039 | | Li Wei | 12,550,000 | RMB Common Shares | 12,550,000 | | China Merchants Bank Co., Ltd. - Huatiamfu Medical Service Flexible Allocation Mixed Securities Investment Fund | 11,809,102 | RMB Common Shares | 11,809,102 | | Goldman, Sachs & Co. | 9,494,934 | RMB Common Shares | 9,494,934 | | Ma Wusheng | 6,876,944 | RMB Common Shares | 6,876,944 | | Sun Pengsheng | 5,781,772 | RMB Common Shares | 5,781,772 | | Qi Chao | 5,403,463 | RMB Common Shares | 5,403,463 | | GF Securities Co., Ltd. Customer Credit Trading Guarantee Securities Account | 4,804,734 | RMB Common Shares | 4,804,734 | | Chen Zengliang | 4,799,110 | RMB Common Shares | 4,799,110 | | Fu Qing | 4,799,110 | RMB Common Shares | 4,799,110 | - Sun Pengsheng, Qi Chao, Fu Qing, Chen Zengliang, and Yang Ziliang collectively hold **68.91%** of Xuzhou Enhua Investment Co., Ltd. and **20.86%** of the company, directly and indirectly controlling **60.95%** of the company's shares, making them the actual controllers and having signed a "Cooperation Agreement" to act in concert[11](index=11&type=chunk) [Significant Matters](index=6&type=section&id=Item%203.%20Significant%20Matters) During the reporting period, the company experienced significant changes in various financial indicators, primarily driven by private placement, changes in settlement methods, increased R&D investment, and higher market promotion expenses [Changes and Reasons for Major Accounting Statement Items and Financial Indicators](index=6&type=section&id=Item%203.1.%20Changes%20in%20Major%20Financial%20Items%20and%20Reasons) During the reporting period, the company's financial indicators underwent significant changes, primarily due to the completion of a private placement, changes in settlement methods, increased R&D investment, and higher market promotion expenses, leading to substantial growth in monetary funds, total assets, capital reserves, and total equity attributable to the parent company - Monetary funds increased by **73.45%** at the end of the period compared to the beginning, mainly due to the proceeds from the private placement completed during the reporting period[14](index=14&type=chunk) - Notes receivable increased by **160.03%** at the end of the period compared to the beginning, primarily due to changes in settlement methods during the reporting period[14](index=14&type=chunk) - Other receivables increased by **297.14%** at the end of the period compared to the beginning, mainly due to advances for marketing personnel's promotion and business expenses, and prepaid R&D expenses during the reporting period[14](index=14&type=chunk) - Inventories increased by **29.35%** at the end of the period compared to the beginning, primarily due to increased stocking during the reporting period[14](index=14&type=chunk) - Construction in progress increased by **35.08%** at the end of the period compared to the beginning, mainly due to increased fixed asset investments in Jiawang Industrial Park and Tongshan Industrial Park[14](index=14&type=chunk) - Total assets increased by **35.72%** at the end of the period compared to the beginning, primarily due to the proceeds from the private placement completed during the reporting period[14](index=14&type=chunk) - Short-term borrowings decreased by **34.68%** at the end of the period compared to the beginning, mainly due to the company repaying part of its bank loans with its own funds during the reporting period[14](index=14&type=chunk) - Accounts payable increased by **29.60%** at the end of the period compared to the beginning, primarily due to increased purchases of inventory goods during the reporting period[14](index=14&type=chunk) - Capital reserves increased by **4,519.27%** at the end of the period compared to the beginning, mainly due to the impact of the private placement completed during the reporting period[14](index=14&type=chunk) - Total equity attributable to the parent company increased by **69.86%** at the end of the period compared to the beginning, primarily due to the private placement completed and increased net profit during the reporting period[14](index=14&type=chunk) - Administrative expenses increased by **26.61%** year-on-year, mainly due to increased R&D investment, staff salaries, and depreciation during the reporting period[15](index=15&type=chunk) - Cash received relating to other operating activities decreased by **43.89%** in the current period compared to the same period last year, mainly due to a decrease in deposits received by subsidiaries during the reporting period[15](index=15&type=chunk) - Cash paid to and for employees increased by **33.37%** in the current period compared to the same period last year, mainly due to an increase in employees and higher employee salaries during the reporting period[15](index=15&type=chunk) - Cash paid relating to other operating activities increased by **39.95%** in the current period compared to the same period last year, mainly due to increased market development, maintenance, and academic promotion expenses during the reporting period[15](index=15&type=chunk) - Net cash flow from investing activities decreased by **112.54%** in the current period compared to the same period last year, mainly due to increased payments for the acquisition of fixed assets and wealth management products during the reporting period[15](index=15&type=chunk) - Net cash flow from financing activities increased by **1,303.31%** in the current period compared to the same period last year, mainly due to the proceeds from the private placement completed during the reporting period[15](index=15&type=chunk) - Net increase in cash and cash equivalents increased by **300.31%** in the current period compared to the same period last year, mainly due to the proceeds from the private placement completed during the reporting period[15](index=15&type=chunk) [Progress, Impact, and Solutions of Significant Matters](index=6&type=section&id=Item%203.2.%20Progress%2C%20Impact%2C%20and%20Solutions%20of%20Significant%20Matters) During the reporting period, the company had no significant matters requiring disclosure regarding their progress, impact, or solutions - The company had no significant matters requiring explanation of their progress, impact, or solutions during the reporting period[16](index=16&type=chunk) [Commitments by the Company or Shareholders Holding 5% or More](index=6&type=section&id=Item%203.3.%20Commitments%20by%20Company%20or%20Major%20Shareholders) The company and its major shareholders strictly fulfilled various commitments during the reporting period, including avoiding horizontal competition, preventing related parties from harming other shareholders' interests through related transactions, not occupying company funds, and ensuring the company's independent operation, with actual controllers also committing not to terminate their acting-in-concert agreement for three years and some shareholders pledging not to reduce their holdings within specific periods Fulfillment Status of Commitments | Commitment Reason | Promising Party | Commitment Content | Commitment Date | Commitment Period | Fulfillment Status | | :--- | :--- | :--- | :--- | :--- | :--- | | Commitments Made During Asset Restructuring | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to avoid horizontal competition | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to prevent related parties from harming other shareholders' interests through related transactions | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment regarding fund occupation | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to ensure the company's independent operation | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Chen Zengliang; Fu Qing; Qi Chao; Sun Pengsheng; Yang Ziliang | Not to reduce company shares within the next six consecutive months | September 04, 2014 | 6 months | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang | Commitment not to terminate the acting-in-concert agreement within the next three years | March 18, 2015 | 3 years | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Company Directors, Supervisors, Senior Management | Commitment regarding share trading during tenure | July 23, 2008 | During tenure and within twelve months after six months of resignation declaration | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Xuzhou Enhua Investment Co., Ltd. and Company Directors, Supervisors, Senior Management | Not to reduce company shares within the next 6 months from the announcement date | July 09, 2015 | 6 months | Strictly Fulfilled During Reporting Period | [2015 Annual Operating Performance Forecast](index=8&type=section&id=Item%203.4.%202015%20Annual%20Performance%20Forecast) The company forecasts a **15.00% to 35.00%** increase in net profit attributable to shareholders of the listed company for 2015, ranging from **RMB 256.76 million to RMB 301.41 million**, primarily driven by stable growth in main business revenue 2015 Annual Operating Performance Forecast | Indicator | Change Range | Change Range (RMB 10,000) | 2014 Net Profit (RMB 10,000) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | 15.00% To 35.00% | 25,676 To 30,141 | 22,327 | - The main reason for the performance change is the stable growth in the company's main business revenue[19](index=19&type=chunk) [Securities Investment Status](index=8&type=section&id=Item%203.5.%20Securities%20Investment) The company had no securities investments during the reporting period - The company had no securities investments during the reporting period[20](index=20&type=chunk) [Holdings in Other Listed Companies](index=8&type=section&id=Item%203.6.%20Holdings%20in%20Other%20Listed%20Companies) The company did not hold equity in any other listed companies during the reporting period - The company did not hold equity in any other listed companies during the reporting period[21](index=21&type=chunk)